

**RESOLUTION**

**Regarding: Approval of the 2026 Business Plan  
Central Pharmaceutical Joint Stock Company No. 25**

**BOARD OF DIRECTORS OF CENTRAL PHARMACEUTICAL JOINT  
STOCK COMPANY 25**

- *Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;*
- *Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019;*
- *Based on the Charter of Central Pharmaceutical Company No. 25; Based on the Internal Regulations on Corporate Governance of Central Pharmaceutical Company No. 25;*
- *Based on Proposal No. 30/TTr-TW25 dated January 26, 2026, regarding the approval of the 2026 business plan by the Company's Executive Board;*
- *Based on the results of the written consultation with the Board of Directors members dated February 3, 2026,*

**RESOLUTION**

**Article 1:** The business plan for 2026, to be presented at the 2026 Annual General Meeting of Shareholders, is hereby approved. Specifically, the main targets are as follows:

- *Total revenue: VND 130 billion.*
- *Profit before tax: VND 2.5 billion.*

**Article 2:** The members of the Board of Directors and the General Management Board are responsible for implementing this Resolution. This Resolution takes effect from the date of signing./.

*Recipients:*

- *HNX, Website [www.uphace.vn](http://www.uphace.vn);*
- *Members of the Board of Directors and Supervisory Board;*
- *Board of Directors' archives.*

